Abstract:4052 Background: There was no prospective randomized study compared taxanes plus fluoropyrimidine versus platinum plus fluoropyrimidine in adjuvant chemotherapy for advanced gastric cancer. Nab-paclitaxel is nanoparticle albumin-bound formulation, showed a potentially efficacy in gastric cancer. We designed this trial to compare the effective and safety of AS and CapeOX regimen for gastric adenocarcinoma adjuvant therapy. Methods: Patients with stage III gastric or gastroesophageal junction adenocarcinoma who had D2 surgery and achieved R0 resection were randomized 1:1 to AS group and CapeOX. Randomization was stratified by differentiation type (differentiated vs. undifferentiated) and AJCC/UICC pathological stage (IIIA vs. IIIB, IIIC). AS group: Nab-paclitaxel 100 mg/m 2 on d1 and d8; S-1 80-120mg/d, p.o., bid on d1-d14; repeated every 21 days for 8 cycles. CapeOX group: oxaliplatin 130 mg/m 2 on d1; capecitabine 1000 mg/m 2 , p.o., bid on d1-d14; repeated every 21 days for 8 cycles. The primary endpoint is 3-year disease-free survival (3-year-DFS) rate, the secondary endpoints included overall survival (OS), and safety. Results: Between March, 2020 to Jan, 2022, 146 subjects were enrolled to receive either AS regimen (n = 71) or CapeOX regimen (n = 75). The baseline characteristics between two arms were generally balanced. The 1-year DFS rate was 95.50% and 72.84% in AS and CapeOX group, respectively. At the cutoff date, 3 patients (the recurrence sites were peritoneum [n = 1], locoregional [n = 1] and distant [n = 1]) in AS group had relapsed, compared with 10 patients (peritoneum [n = 2], locoregional [n = 4] and distant [n = 4]) in CapeOX group. 4 subjects in CapeOX group died compared with 0 in AS group. A total of 42 patients (AS, n = 21 [29.58%]; CapeOX, n = 21 [28.00%]) needed dose reduction main due to hematological toxicity. The median relative dose intensity of Nab-paclitaxel, S-1, oxaliplatin and capecitabine was 82.55%, 91.30%%, 83.16%% and 78.95%, respectively. Treatments were delayed in 82 of 297 (27.61%, 24 due to hematological and 15 due to non-hematological toxicity) cycles at AS group and in 100 of 319 (31.35%, 18 due to hematological and 13 due to non-hematological toxicity) cycles at CapeOX group. There were 34 (47.89%) patients in AS group and 30 (40.00%) patients in CapeOX group occurred treatment-related adverse events (TRAEs), though most of them were grade I-II. Main grade III-IV AEs were neutropenia (28.16% in AS group vs 8.00% in CapeOX group), leucopenia (15.49% vs 1.33%), thrombocytopenia (0% vs 8.00%) and anemia (5.63% vs 1.33%). Conclusions: Adjuvant AS regimen showed a trend towards better DFS compared with CapeOX regimen, and is a potentially regimen for stage III gastric cancer after curative D2 gastrectomy, with tolerable toxicity. Long-term survival benefit requires more data. Clinical trial information: NCT04135781.

Clinical research of stage Ⅲb and Ⅲc colon cancer treating with Capecitabine as consolidation chemotherapy after adjuvant chemotherapy

Meta-Analysis Of Capecitabine-Based Chemotherapy Versus Capecitabine-Free Chemotherapy In Patients With Metastatic Breast Cancer

Survival analysis of 65 cases with stage Ⅲ colorectal cancer on adjuvant chemotherapy

Postoperative Chemoradiotherapy with Capecitabine and Oxaliplatin Vs. Capecitabine for Pathological Stage N2 Rectal Cancer.

Long-term Survival of an Elderly Female with Metastatic Colon Cancer after Treated with Capecitabine Monotherapy

A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection.

Postoperative Capecitabine With Concurrent Intensity-Modulated Radiotherapy Or Three-Dimensional Conformal Radiotherapy For Patients With Stage Ii And Iii Rectal Cancer

Clinical observation of postoperative hepatic arterial infusion and systemic adjuvant chemotherapy in patients with stage Ⅲcolorectal cancer

Outcome of Locally Advanced Rectal Cancer Patients Treated with Radical Surgery Followed by Concurrent Capecitabine and Radiotherapy

Toxicity Evaluation Of Capecitabine Concurrent Chemoradiotherapy For Stage Ii And Iii Rectal Cancer

Interim Analysis of Postoperative Chemoradiotherapy with Capecitabine and Oxaliplatin Versus Capecitabine Alone for Pathological Stage II and III Rectal Cancer: a Randomized Multicenter Phase III Trial

One to Two Cycles of Consolidation Chemotherapy With Capecitabine After Neoadjuvant Chemoradiotherapy Does Not Benefit Low-Risk Patients With Locally Advanced Middle-Low Rectal Cancer

The Effect of Oxaliplatin Plus Capecitabine in Combination with Radiation for Locally Advanced Lower or Middle Sited Rectal Carcinoma

Consolidation Chemotherapy with Capecitabine after Neoadjuvant Chemoradiotherapy in High-Risk Patients with Locally Advanced Rectal Cancer: Propensity Score Study

A retrospective analysis of the efficacy and safety of capecitabine plus oxaliplatin (CapeOX) and docetaxel plus S-1 (DS) as adjuvant chemotherapy for pathological stage III (p stage III) gastric cancer (GC).

Comparison of Concurrent Chemoradiotherapy with Capecitabine and Oxaliplatin Versus Capecitabine Alone in Stage Ⅱ/Ⅲ Rectal Cancer Patients after Radical Operation

Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer

The studies on adjuvant chemotherapy for Dukes B colorectal cacinoma

Adjuvant chemotherapy in ypStage III locally advanced rectal cancer after neoadjuvant treatment with an oxaliplatin-based regimen.

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis